Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight.
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2017
At a glance
- Drugs NNC 0174 0833 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 07 Aug 2017 Planned End Date changed from 8 Dec 2017 to 7 Dec 2017.
- 07 Aug 2017 Planned primary completion date changed from 8 Dec 2017 to 7 Dec 2017.
- 16 Nov 2016 Status changed from not yet recruiting to recruiting.